Mountain Medical Road to Recovery is excited to announce we have merged with Front Range Clinic. We are now FRC/ Road to Recovery. Please visit the Front Range Clinic website for information about our services.

Integrated Functional Addiction & Pain Medicine

At Road to Recovery our mission is to provide innovative therapies and treatments to allow each patient to detoxify from substance use, control pain and recover to enjoy a healthy happy life. We want to help you thrive.

Detoxification & Medication Assisted Recovery

Outpatient Recovery, Buprenorphine/Naloxone (Suboxone), Naltrexone (Vivitrol), Naloxone

Psychotherapy & Group Therapy

Individual and Family Therapy, Substance Abuse Recovery Groups, Pain Support Groups, Intensive Outpatient Therapy & Education

Innovative Pain Management

Medications, procedures, alternative therapies and respectful medical management to reduce pain and increase function.

Our Mission

We want you to thrive

At Road to Recovery our mission is to provide innovative therapies and treatments to allow each patient to manage physical and emotional pain and detoxify from substance use. Our goal is to help every patient recover to enjoy a healthy, happy life.
We provide medical support for out-patient detoxification. We work hand-in-hand with our patients to provide ongoing medical and behavioral health support for lifelong recovery. At each Road to Recovery location, we have doctors, therapists, and specialists available to individualize the treatment path for each patient. We believe that aligning the treatment plan with the needs and beliefs of each patient helps to reinforce long- term recovery and wellness. Our providers take pride in staying up to date on the latest research and innovations to help each patient recover and maximize physical and mental health.
We want to help each patient thrive. We provide comprehensive physical and mental evaluation to identify the roots of the issues. We then work with the patient to choose the best treatment to control pain, manage physical and mental co-occurring issues and optimize function and joyful living.

From the Blog

Read our latest on pain management, detox and recovery, psychotherapy and more.

Steamboat locals to testify for state-funded addiction treatment program at state Capitol

Steamboat locals to testify for state-funded addiction treatment program at state Capitol

Colorado lawmakers are attempting to pass a bill that would provide medication-assisted treatment programs to addicts across the state. The bill unanimously passed the Senate last week and heads to the House of Representatives. (Stock photo, Shutterstock)

STEAMBOAT SPRINGS — Longtime Steamboat Springs resident Melinda McDowell will be one among many recovering addicts heading to the state Capitol in Denver on Friday to testify in support of a bill that would expand a medication-assisted treatment program. read more…

The Fentanyl Failure

The Fentanyl Failure

Despite mounting deaths and warnings, the Obama administration did not take extraordinary measures to confront an extraordinary crisis, experts say

read more…

Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities

Primary Care and the Opioid-Overdose Crisis — Buprenorphine Myths and Realities

New England Journal of Medicine – Despite widespread awareness of the opioid-overdose crisis, the epidemic continues to worsen. In 2016, there were 42,249 opioid-overdose deaths in the United States, a 28% increase from the previous year. According to the National Center for Health Statistics, life expectancy in the United States dropped in 2016 for the second consecutive year, partly because of an increase in deaths from unintentional injuries, including overdoses. It was the first 2-year decline since the 1960s. How can we be making so little progress?

Annual Change in Buprenorphine and Methadone Volume Dispensed in the United States, 2006–2016.

In part, the overdose crisis is an epidemic of poor access to care. One of the tragic ironies is that with well-established medical treatment, opioid use disorder can have an excellent prognosis. Decades of research have demonstrated the efficacy of medications such as methadone and buprenorphine in improving remission rates and reducing both medical complications and the likelihood of overdose death.1 Unfortunately, treatment capacity is lacking: nearly 80% of Americans with opioid use disorder don’t receive treatment.2 Although access to office-based addiction treatment has increased since federal approval of buprenorphine, data from the Drug Enforcement Administration (DEA) reveal that annual growth in buprenorphine distribution has been slowing, rather than accelerating to meet demand (see graph). To have any hope of stemming the overdose tide, we have to make it easier to obtain buprenorphine than to get heroin and fentanyl.

We believe there’s a realistic, scalable solution for reaching the millions of Americans with opioid use disorder: mobilizing the primary care physician (PCP) workforce to offer office-based addiction treatment with buprenorphine, as other countries have done. As of 2017, according to the Kaiser Family Foundation, there were more than 320,000 PCPs, plus a broad workforce of nurse practitioners and physician assistants, treating U.S. adults. In contrast, there are just over 3000 diplomates of the American Board of Addiction Medicine, and only 16% of 52,000 active psychiatrists had a waiver to prescribe buprenorphine in 2015 (moreover, 60% of U.S. counties have no psychiatrists).3 Training enough addiction medicine or psychiatric specialists would take years, and most methadone treatment programs are already operating at 80% of capacity or greater.4

However, PCPs and other generalists, including pediatricians, obstetrician–gynecologists, and physicians who treat human immunodeficiency virus (HIV) infection, are well situated to provide buprenorphine treatment. Many have risen to this challenge: PCPs are responsible for most ambulatory care visits for buprenorphine treatment. The importance of mobilizing the PCP workforce while ensuring the availability of sufficient specialists is not unique to the opioid-overdose crisis. During the height of the HIV/AIDS epidemic, for example, access to antiretroviral therapy was urgently needed. Although initially specialists were more likely to prescribe antiretrovirals, by 1990 equal percentages of patients were receiving antiretroviral therapy from PCPs and from specialists.

Myths and Realities of Opioid Use Disorder Treatment.

How can we promote adoption of buprenorphine treatment by PCPs? The relevant federal and state regulatory barriers could be addressed, but they reflect a deeper problem: stigma and myths about buprenorphine treatment inhibit its acceptance (see table).

The first myth is that buprenorphine is more dangerous than other interventions physicians master during training. In fact, PCPs regularly prescribe more complicated and risky treatments. Titrating insulin, starting anticoagulants, and prescribing full-agonist opioids for pain are often more challenging and potentially harmful than prescribing buprenorphine. Yet this perception has been cemented by federal policy. The Drug Addiction Treatment Act of 2000 requires that physicians complete 8 hours of training (sacrificing a full day of work) and apply for a DEA waiver to begin prescribing buprenorphine. After passing these hurdles, physicians are authorized to treat only a limited number of patients. These requirements make buprenorphine treatment intimidating.

The first step toward debunking this myth would be to scale back these federal regulations. Training in appropriate buprenorphine treatment optimizes outcomes and minimizes risks, but such training could be incorporated into existing medical education. All physicians could be trained during medical school and residency, so that both PCPs and other specialists would be equipped to offer this treatment — and, more generally, would be comfortable in caring for patients with opioid use disorder.

The second myth is that buprenorphine is simply a “replacement” and that patients become “addicted” to it — a belief still held by some physicians. But addiction is defined not by physiological dependence but by compulsive use of a drug despite harm. If relying on a daily medication to maintain health were addiction, then most patients with chronic health conditions such as diabetes or asthma would be considered addicted.

A closely related myth is that abstinence-based treatment, usually implying short-term detoxification and rehabilitation, is more effective than medication for addiction treatment. This belief underpins widespread advocacy for more substance use treatment “beds” as a key solution for the overdose crisis. But whereas there’s a strong evidence base for buprenorphine and methadone treatment, no study has shown that detoxification or 30-day rehabilitation programs are effective at treating opioid use disorder.5 In fact, these interventions may increase the likelihood of overdose death by eliminating the tolerance that a patient had built up. To address myths about the effectiveness of buprenorphine and abstinence treatment, we can start with advocacy and education about the evidence to counter misleading depictions of addiction treatment in the media.

Another myth is that providing buprenorphine treatment is particularly onerous and time consuming. In our experience, it is no more burdensome than treating other chronic illnesses. A typical visit includes assessing medication adherence, examining disease control (e.g., cravings and use), titrating doses, and ordering laboratory tests. Moreover, buprenorphine treatment provides one of the rare opportunities in primary care to see dramatic clinical improvement: it’s hard to imagine a more satisfying clinical experience than helping a patient escape the cycle of active addiction. The fact that, for in-office inductions, patients must wait until withdrawal begins to take an initial buprenorphine dose under observation undoubtedly contributes to fears about the demand on physicians’ time. But this process has not been shown to be more effective than having patients start the medication outside the office. In fact, buprenorphine management provided by a PCP is effective with or without additional psychosocial interventions. This myth could be countered by developing and disseminating protocols emphasizing home induction and primary care models for treatment, including approaches consistent with efforts to transform practices into patient-centered medical homes.

Finally, some observers believe that physicians should simply stop prescribing so many opioids. The crisis began with increased opioid prescribing, yet as prescribing rates have fallen since 2011, overdose deaths have accelerated. If prescribing patterns were the sole driver of overdoses, then decreased prescribing should have had a measurable effect on opioid-related mortality over the past several years. In reality, research has demonstrated that interventions like the introduction of abuse-deterrent Oxycontin, which reduce access to frequently misused prescription opioids, have resulted in people shifting their opioid of choice predominantly to heroin. Rising overdose mortality despite decreasing opioid prescribing suggests that merely reducing the prescription-opioid supply will have little positive short-term impact. Reducing prescribing could even increase the death toll as people with opioid use disorder or untreated pain shift into the unstable, illicit drug market. Instead, we need safer, more thoughtful opioid prescribing and accessible support, such as electronic consultations with addiction specialists, to help physicians offer buprenorphine for people with opioid use disorder.

We are in the midst of a historic public health crisis that demands action from every physician. Without dramatic intervention, life expectancy in the United States will continue to decline. Mobilizing the PCP workforce to offer office-based buprenorphine treatment is a plausible, practical, and scalable intervention that could be implemented immediately. The opioid-overdose epidemic is complex and will require concerted efforts on multiple fronts, but few other evidence-based actions would have such an immediate lifesaving effect. It won’t be easy, but we are confident that U.S. PCPs have the clinical skill and grit to take on this challenge.

Your Health Starts Here

Flexible appointments
For urgent care please call 911

Call to make an appointment

Steamboat # 970-761-2207
Lakewood # 303-434-8484
Mobile Outposts # 970-846-1231
Fax # 206-350-8698

Better Health Care is Our Mission

Call us now. Appointments are Available.

Phone

Steamboat # 970-761-2207
Lakewood # 303-434-8484

Fax # 206-350-8698

Mobile Outposts # 970-846-1231

Locations

Steamboat Springs Location |
320 Oak Street Steamboat Springs, CO 80477

Lakewood Location | 393 South Harlan Street, #103 Lakewood, Colorado 80226

 

Mobile Outpost Locations

Oak Creek | Hayden | Kremmling Granby | Fraser | Jackson

Email 1Rd2Recovery@gmail.com

Mailing

Mail: PO Box 773705 Steamboat Springs, CO 80477

Packages: 200 Lincoln Ave. 773705 Steamboat Springs, CO 80477